-
4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma
Thursday, April 27, 2017 - 11:05am | 559Following Akebia Therapeutics Inc's (NASDAQ: AKBA) announcement of an expanded agreement with Otsuka (OTC: OTSKY) to develop and commercialize Vadadustat in Europe, China and Other Territories, HC Wainwright said in a note that the European partnership provides strong economics, removing any...
-
Upside Of 124% Expected For Akebia Therapeutics Following Vadadustat Collaboration
Wednesday, April 26, 2017 - 9:10am | 308Analysts at JMP Securities believe Akebia Therapeutics Inc (NASDAQ: AKBA), a biopharmaceutical company that develops therapeutics based on hypoxia-inducible factor (HIF) biology, could deliver investors a triple-digit percentage return. JMP's Michael King maintains an Outperform rating on Akebia's...
-
Exclusive: Following Up Akebia, Johnson & Johnson's Research And License Agreement
Friday, February 17, 2017 - 10:21am | 909On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) signed a $1 million research and license agreement with Johnson & Johnson (NYSE: JNJ) to access hundreds of hypoxia inducible factor (HIF)-targeted compounds. This access includes a coveted preclinical candidate for inflammatory bowel disease (...